Livforsakringsbolaget Skandia Omsesidigt Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Livforsakringsbolaget Skandia Omsesidigt grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 73.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 867 shares of the medical device company’s stock after buying an additional 367 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in DexCom were worth $108,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DXCM. Daiwa Securities Group Inc. raised its holdings in shares of DexCom by 4.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 56,725 shares of the medical device company’s stock worth $7,039,000 after purchasing an additional 2,339 shares during the last quarter. HealthInvest Partners AB purchased a new position in shares of DexCom during the fourth quarter worth $2,241,000. Desjardins Global Asset Management Inc. raised its holdings in shares of DexCom by 15.7% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 2,074 shares of the medical device company’s stock worth $257,000 after purchasing an additional 282 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of DexCom during the fourth quarter worth $302,000. Finally, Keel Point LLC purchased a new position in shares of DexCom during the fourth quarter worth $209,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. In the last three months, insiders have sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $134.30 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The firm has a market capitalization of $51.78 billion, a price-to-earnings ratio of 102.52, a PEG ratio of 2.30 and a beta of 1.20. The company’s 50-day moving average is $129.35 and its two-hundred day moving average is $116.41. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the business posted $0.34 EPS. DexCom’s revenue was up 26.9% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 1.76 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on DXCM shares. Raymond James raised their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. UBS Group lifted their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $141.40.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.